Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
adequacy, antiobiotic, appellate, argument, authoritative, BC, brand, broth, campaign, captioned, cellular, Cir, codifying, compound, concurrently, curve, deadline, default, Donald, downturn, environment, ESPP, exact, exceeded, expedite, Feb, float, floating, France, Gram, hypothetical, insider, Italy, Kingdom, Lifescale, light, lobbying, Luminex, MCA, methodology, microdilution, mode, monomicrobial, morphokinetic, neutralize, oral, penalize, perspective, Pheno, PhenoTest, pipettor, PPV, preliminary, Quantamatrix, repatriation, repeal, RUO, sensor, shipment, swing, Trump, twenty, verification, week, withholding, workup, yeast
Filing tables
Filing exhibits
AXDX similar filings
Filing view
External links
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in the following Registration Statements:
(1) | Registration Statement (Form S-8 No. 333-187439) pertaining to the Accelerate Diagnostics, Inc. 2012 Omnibus Equity Incentive Plan, |
(2) | Registration Statement (Form S-8 No. 333-199992) pertaining to the Accelerate Diagnostics, Inc. 2012 Omnibus Equity Incentive Plan, and |
(3) | Registration Statement (Form S-8 No. 333-213072) pertaining to the Accelerate Diagnostics, Inc. 2016 Employee Stock Purchase Plan; |
of our reports dated February 27, 2017, with respect to the financial statements of Accelerate Diagnostics, Inc. and the effectiveness of internal control over financial reporting of Accelerate Diagnostics, Inc., included in this Annual Report (Form 10-K) of Accelerate Diagnostics, Inc. for the year ended December 31, 2016.
/s/ Ernst & Young LLP
Phoenix, Arizona
February 27, 2017